Black Seed Oil and Heart Health: What Trials Measured, and What They Never Did
Black seed oil and heart health is one of the most confidently written topics on the internet, and one of the least carefully defined. Almost every article you will find describes a list of numbers that moved in a trial — blood pressure, cholesterol, a few inflammatory markers — and then quietly lets the reader assume those numbers stand in for something else entirely: fewer heart attacks, fewer strokes, more years alive. They do not, and no study of Nigella sativa has ever measured whether they do. This article is about that gap, because understanding it is more useful than another list of markers.
For our own oil, see our cold-pressed Ethiopian black seed oil.
The Short Answer
- Every human trial of black seed oil in this area has measured cardiovascular risk factors — blood pressure, lipids, glucose, inflammatory markers — not cardiovascular events. The largest review says so in its own title.
- That review is Jafari A and colleagues, Pharmacological Research 2025;219:107882 (PMID 40714301): 82 randomised trials, 5,026 participants, doses from 200 to 4,600 mg/day, durations from 1 to 48 weeks. Its conclusion is that N. sativa "could be a promising adjunct therapy for improving cardiovascular disease risk factors".
- No trial has reported a heart attack, a stroke, a hospital admission or a death as an outcome. There is no evidence base at all on hard cardiovascular endpoints.
- Pooled blood-pressure effects are small and highly inconsistent: about −3 mmHg systolic, with heterogeneity between studies of 59% to 85%. In the 2016 meta-analysis the effect was seen in favour of powdered seed rather than oil.
- An umbrella review of 20 meta-analyses graded 88 of 110 outcome indicators as very low certainty, and rated 15 of the 20 reviews critically low on methodological quality.
- Sidr & Stone publishes an independently verified thymoquinone figure of 2.67% per batch. That is a quality claim about a bottle, not a health claim about a heart. If you have a diagnosed cardiovascular condition or take medication, speak to your GP, pharmacist or cardiologist before adding anything.
What "Heart Health" Actually Means in the Research
In cardiovascular medicine there are two kinds of outcome. Surrogate markers are measurements taken from a blood sample or a cuff — blood pressure, LDL cholesterol, C-reactive protein. Hard endpoints are events that happen to people: myocardial infarction, stroke, revascularisation, cardiovascular death. Surrogates are cheap and fast to measure. Endpoints are what medicine actually cares about, and the two do not always move together.
The entire Nigella sativa cardiovascular literature sits on the surrogate side of that line. Not because the researchers were careless, but because event trials need thousands of participants followed for years, and nobody has funded one. It is worth naming plainly: the reason there is no evidence about heart attacks is that the question has never been asked.
The Largest Review: 82 Trials, and a Title That Tells You Everything
The most comprehensive synthesis to date is a GRADE-assessed systematic review and dose-response meta-analysis by Jafari and colleagues, published in Pharmacological Research in 2025. It pooled 82 studies published between 2008 and 2024, covering 5,026 participants, with interventions running from one week to 48 weeks and doses from 200 to 4,600 mg per day.
The list of measures that improved is genuinely long: body fat percentage, BMI, waist circumference, weight, systolic and diastolic blood pressure, mean arterial pressure, fasting blood sugar, HbA1c, CRP and hs-CRP, IL-6, TNF-α, ICAM-1 and VCAM-1, atherogenic index, HDL-C, LDL-C, total cholesterol, triglycerides, VLDL-C, and several liver, kidney and antioxidant markers. It is a striking list. It is also, without exception, a list of risk factors — which is precisely what the review's title says it is.
| Jafari et al. 2025 (PMID 40714301) | Detail |
|---|---|
| Studies pooled | 82 (79 quantitative, 3 qualitative), published 2008–2024 |
| Participants | 5,026 |
| Dose range | 200–4,600 mg/day |
| Duration range | 1–48 weeks |
| Outcomes measured | Anthropometric, blood pressure, glycaemic, lipid, inflammatory, oxidative and organ-function markers |
| Cardiovascular events measured | None |
| Deaths or hospital admissions measured | None |
| Authors' own conclusion | A "promising adjunct therapy for improving cardiovascular disease risk factors" |
Lipids are the part of this picture with the deepest literature, and we have covered them separately rather than repeat them here — see our article on black seed oil and cholesterol for the lipid trials in detail.
Blood Pressure: About Three Millimetres, and a Detail Most Articles Omit
Two meta-analyses anchor the blood-pressure question, and they agree on the size of the pooled effect while disagreeing with the way the topic is usually marketed.
Sahebkar A, Soranna D, Liu X, Thomopoulos C, Simental-Mendia LE, Derosa G, Maffioli P and Parati G, writing in the Journal of Hypertension in 2016, pooled 11 randomised trials covering 860 hypertensive or normotensive individuals over a mean of 8.3 weeks. They reported a difference in reduction versus control of −3.26 mmHg systolic (95% CI −5.10 to −1.42) and −2.80 mmHg diastolic (95% CI −4.28 to −1.32). Their finding included something rarely quoted: powder and oil preparations behaved differently, and the effect was in favour of the powder.
Kavyani Z and colleagues updated the picture in Phytotherapy Research in 2023, reporting −3.06 mmHg systolic (95% CI −3.89 to −2.22) and −2.69 mmHg diastolic (95% CI −3.72 to −1.66). Both results were statistically significant. Both also carried extreme statistical heterogeneity — I² of 84.7% and 97.3% respectively — which means the individual trials were pulling in genuinely different directions and the pooled average conceals more than it reveals.
| Meta-analysis | Trials / participants | Systolic (WMD) | Diastolic (WMD) | Heterogeneity (I²) | Notable caveat |
|---|---|---|---|---|---|
| Sahebkar et al. 2016, J Hypertens 34(11):2127–2135 (PMID 27512971) | 11 RCTs / 860 | −3.26 mmHg (−5.10 to −1.42) | −2.80 mmHg (−4.28 to −1.32) | 59% / 60% | Effect favoured powder over oil; short-term only |
| Kavyani et al. 2023, Phytother Res 37(8):3224–3238 (PMID 37341696) | Updated RCT set | −3.06 mmHg (−3.89 to −2.22) | −2.69 mmHg (−3.72 to −1.66) | 84.7% / 97.3% | Very high heterogeneity across trials |
We sell an oil. The most-cited blood-pressure meta-analysis in this field found the signal in the powder. We would rather tell you that than leave it out.
How Certain Is Any of This? The GRADE Answer
There is a formal system for answering exactly this question, and somebody has applied it. Li Z, Wang Y, Xu Q, Ma J, Li X, Yan J, Tian Y, Wen Y and Chen T published an overview of systematic reviews in Frontiers in Nutrition in 2023, assessing 20 meta-analyses of N. sativa using AMSTAR-2 for methodological quality and GRADE for certainty of evidence.
Their findings: of the 20 reviews, one was rated moderate quality, four low, and fifteen critically low. Across 110 outcome indicators, five were graded moderate certainty, 17 low, and 88 very low. The main reasons for downgrading were risk of bias, inconsistency and imprecision. Their conclusion was that clinical efficacy "requires confirmation in high-quality, large-sample, randomized controlled trials".
It is also worth noting where the pooled results are simply null. Hallajzadeh J and colleagues, in Phytotherapy Research in 2020, pooled 50 trials and found no significant effect on C-reactive protein, TNF-α, total antioxidant capacity or malondialdehyde — four of the inflammatory and oxidative markers most often invoked in cardiovascular marketing. Our inflammation article covers that literature in more depth.
Eighty-two trials sounds like a lot. Quantity of evidence and certainty of evidence are different things, and GRADE exists to keep them apart.
Where This Gets Genuinely Risky: Medication
The realistic hazard with black seed oil and heart health is not that it does nothing. It is that somebody with a cardiovascular diagnosis reads an enthusiastic article, adds a supplement to a medication regimen without telling anyone, or — far worse — treats it as a reason to reduce something they were prescribed. Do not do the second thing under any circumstances, and do the first only after a conversation.
Two specific interaction questions are legitimate. If the pooled trials really do shift blood pressure by a few millimetres, then that effect is additive with antihypertensive medication, and the same logic applies to blood-glucose medicines. Separately, Wang Z and colleagues reported in Chemico-Biological Interactions in 2022 that thymoquinone competitively inhibits warfarin 7-hydroxylation via CYP2C9 in vitro, with an IC50 of 11.35 µM, and modelled that intakes above roughly 1 g per day of N. sativa oil might alter warfarin's pharmacokinetics. That is a laboratory prediction, not an observed human interaction — but it is the right thing to raise with an anticoagulant clinic rather than discover later.
| If you... | Sensible default | Who to ask |
|---|---|---|
| Take warfarin or another anticoagulant or antiplatelet | Do not start without advice | Pharmacist or anticoagulant clinic |
| Take blood-pressure medication | Do not start without advice; never adjust a dose yourself | GP or cardiologist |
| Take medication for blood glucose | Do not start without advice | GP or diabetes team |
| Have a diagnosed cardiovascular condition | Treat this article as background reading only | Cardiologist or GP |
| Are pregnant, breastfeeding or trying to conceive | Do not take supplemental doses | Midwife or GP |
| Have surgery scheduled | Declare every supplement you take | Surgical team |
Our drug interactions guide and safety guide go through this in more detail.
Why a Trial Dose Cannot Be Read Off a Retail Bottle
Suppose you read all of the above and still wanted to try the oil as a food. You would immediately hit a practical problem: the trials specify doses in milligrams or millilitres, but the compound they are about — thymoquinone — is present in wildly different amounts depending on which bottle you pick up. Khaikin E, Chrubasik-Hausmann S, Kaya S and Zimmermann BF measured thymoquinone in eleven commercial Nigella sativa products by HPLC-UV for Nutrients in 2022, and found a range from 3.08 to 809.4 mg per 100 g — a more than 260-fold spread.
Two teaspoons of "black seed oil" can differ by more than two orders of magnitude in the substance the research studied. That is the one part of this topic where the evidence is unambiguous, and it is a quality problem rather than a heart problem. See our guide to choosing a high-quality black seed oil and our thymoquinone guide.
Why Sidr & Stone
Nothing on this page is an argument that our oil will do anything for your heart, and we are not going to construct one. The argument we will make is narrower and, we think, more defensible: if you are going to buy black seed oil at all, you should be able to see what is in it. Of the 36 suppliers we evaluated before selecting our seed, the differentiator was not marketing language — it was whether a per-batch thymoquinone figure existed.
- Sidr & Stone's black seed oil is independently verified at 2.67% thymoquinone, tested per batch by Analytice, an ISO-accredited French laboratory, with a Certificate of Analysis you can read for yourself.
- Organically grown Ethiopian highland Nigella sativa, chosen after a 36-supplier evaluation.
- Cold-pressed below 40°C, because thymoquinone is heat-sensitive.
- 100% pure — one ingredient, Nigella sativa seed oil, nothing added.
- Unrefined, which preserves the oil's natural integrity; fine natural sediment is normal.
- Bottled in matte black UV-protective glass, because thymoquinone is light-sensitive.
- Halal certified.
- 10% of profits to charity.
- Fulfilment in the UK, EU, and US.
We will not tell you Sidr & Stone is the strongest or the best — that would be the very claim this article warns against. What we will say is that our thymoquinone figure is 2.67%, independently verified per batch, and the evidence is there to see.
Frequently Asked Questions
Is black seed oil good for heart health?
We cannot say that it is, and we do not claim it. Trials have measured changes in cardiovascular risk markers such as blood pressure, lipids and glucose; none has measured whether those changes translate into fewer cardiovascular events. Black seed oil is a food supplement, not a heart treatment.
Does black seed oil lower blood pressure?
Meta-analyses of short trials report pooled mean differences of roughly −3 mmHg systolic and −2.7 mmHg diastolic versus control, over about eight weeks. Those pooled numbers carry very high heterogeneity, and the 2016 analysis found the effect favoured powdered seed rather than oil. This is a description of published pooled data, not a claim about what will happen to you.
Has any trial shown black seed oil prevents heart attacks or strokes?
No. Not one trial of Nigella sativa has reported myocardial infarction, stroke, hospital admission or cardiovascular death as an outcome. The evidence base on hard cardiovascular endpoints is empty, and any article implying otherwise is going beyond what has been measured.
Is kalonji good for heart patients?
Kalonji is another name for the same seed, so the same evidence applies — and the answer for anyone who is already a "heart patient" is that this is a question for a cardiologist, not a supplement page. Interactions with anticoagulant, antihypertensive and glucose-lowering medication are the main practical concern.
Does a higher thymoquinone percentage mean a better result for the heart?
It does not follow. A higher verified percentage tells you the bottle contains more of the compound the research studied; it does not tell you that more of the compound produces a better clinical outcome, because no trial has tested that. Verification is about knowing what you have bought, nothing more.
Can black seed oil replace my heart or blood-pressure medication?
No, and nobody should attempt it. Prescribed cardiovascular medicines are chosen on the basis of trials that measured events, which black seed oil has never been tested against. Never stop or reduce a prescribed medicine without your doctor's direction.
What should I check before buying black seed oil?
Ask for a per-batch Certificate of Analysis from a named independent laboratory, showing a measured thymoquinone figure rather than an "up to" range. Given the 3.08 to 809.4 mg per 100 g spread found across eleven commercial products, an unverified label carries very little information.
Is black seed oil a medicine?
No. Black seed oil is a food supplement, not a medicine. It has a long traditional history and an interesting body of research around thymoquinone, and can be a worthwhile part of a healthy routine — but it does not cure diseases and is not a substitute for medical care. Be cautious of any black seed oil marketed with specific disease-cure claims.
Final Thoughts
Three objections are worth meeting head-on. The first: three millimetres of mercury is not nothing — population studies show small shifts in average blood pressure matter at scale. That is true, and it is the strongest argument in favour of taking this literature seriously. But the inference that a few millimetres translates into fewer events comes from large drug trials that counted events. Transferring that inference to a supplement whose trials never counted anything is an assumption, and it should be labelled as one.
The second: eighty-two trials and five thousand participants surely amount to strong evidence. Quantity is not certainty. When the GRADE framework was applied across this literature, 88 of 110 outcomes came back very low, and fifteen of twenty reviews were rated critically low on methodology. That is the evidence base describing itself.
The third: if it is just a food, why all the caution? Because the people most likely to read an article like this are the people most likely to be on medication — and the interaction questions around anticoagulants, antihypertensives and glucose-lowering drugs are real, even where the evidence for benefit is thin. Caution and scepticism point the same direction here.
Black seed oil is a food with a long history and a genuinely interesting research literature that has not yet answered the question people most want answered. If you want it in your routine as a food, the honest thing we can offer is a bottle whose contents are measured rather than asserted. Our cold-pressed Ethiopian black seed oil — independently verified at 2.67% thymoquinone — is available now, with fulfilment in the UK, EU, and US.
Shop Sidr & Stone Cold-Pressed Ethiopian Black Seed Oil — Verified 2.67% Thymoquinone →
References
- Jafari A, Mardani H, Faghfouri AH, Fashtali ZM, Hashemi M, Yousefabady MA, Javid R, Golabi S, Arghavan B, Musazadeh V, Naghashpour M. Does Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review and dose-response meta-analysis of 82 randomized controlled trials. Pharmacological Research 2025;219:107882. PMID 40714301. doi:10.1016/j.phrs.2025.107882
- Sahebkar A, Soranna D, Liu X, Thomopoulos C, Simental-Mendia LE, Derosa G, Maffioli P, Parati G. A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. Journal of Hypertension 2016;34(11):2127–2135. PMID 27512971. doi:10.1097/HJH.0000000000001049
- Kavyani Z, Musazadeh V, Safaei E, Mohammadi Asmaroud M, Khashakichafi F, Ahrabi SS, Dehghan P. Antihypertensive effects of Nigella sativa supplementation: an updated systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research 2023;37(8):3224–3238. PMID 37341696. doi:10.1002/ptr.7891
- Li Z, Wang Y, Xu Q, Ma J, Li X, Yan J, Tian Y, Wen Y, Chen T. Nigella sativa and health outcomes: an overview of systematic reviews and meta-analyses. Frontiers in Nutrition 2023;10:1107750. PMID 37057067. doi:10.3389/fnut.2023.1107750
- Hallajzadeh J, Milajerdi A, Mobini M, Amirani E, Azizi S, Nikkhah E, Bahadori B, Sheikhsoleimani R, Mirhashemi SM. Effects of Nigella sativa on glycemic control, lipid profiles, and biomarkers of inflammatory and oxidative stress: a systematic review and meta-analysis of randomized controlled clinical trials. Phytotherapy Research 2020;34(10):2586–2608. PMID 32394508. doi:10.1002/ptr.6708
- Wang Z, Wang Z, Wang X, Lv X, Yin H, Jiang L, Xia Y, Li W, Li W, Liu Y. Potential food-drug interaction risk of thymoquinone with warfarin. Chemico-Biological Interactions 2022;365:110070. PMID 35921950. doi:10.1016/j.cbi.2022.110070
- Khaikin E, Chrubasik-Hausmann S, Kaya S, Zimmermann BF. Screening of thymoquinone content in commercial Nigella sativa products to identify a promising and safe study medication. Nutrients 2022;14(17):3501. PMID 36079759. doi:10.3390/nu14173501
Disclaimer: This article describes what published research on black seed oil and cardiovascular risk markers has and has not measured at the time of writing; research findings and product specifications may change, and readers should check current sources. It is not a recommendation to use black seed oil for blood pressure, cholesterol, cardiovascular disease or any related condition. Black seed oil is a food supplement, not a medicine, and is not a substitute for medical treatment of any condition. Never stop, reduce or alter prescribed medication without your doctor's direction. For any health concern, consult a qualified medical professional.